Pembrolizumab plus chemotherapy for pleural mesothelioma

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

(2023) Nicholas J. Vogelzang et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

(2023) Quincy Chu et al.   LANCET

Living with mesothelioma: A systematic review of patient and caregiver psychosocial support needs

(2022) Lauren J. Breen et al.   PATIENT EDUCATION AND COUNSELING

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

(2021) Paul Baas et al.   LANCET

Assessment of Global Trends in the Diagnosis of Mesothelioma From 1990 to 2017

(2021) Zhen Zhai et al.   JAMA Network Open

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

(2021) S. Popat et al.   ANNALS OF ONCOLOGY

Malignant Pleural Mesothelioma

(2021) Calvin Sidhu et al.   CLINICS IN CHEST MEDICINE

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

(2016) Gérard Zalcman et al.   LANCET

Postmortem Findings of Malignant Pleural Mesothelioma

(2012) Rhian S. Finn et al.   CHEST

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

(2011) Tom Treasure et al.   LANCET ONCOLOGY